Cerluten
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Our verdict SKIP-FOR-NOW LOW
Mechanism precision is very thin, evidence is thin Russian-only with zero Western replication, and the broader Khavinson short-peptide framework itself is contested — many cleaner liver-protection options (NAC, milk thistle, choline) cover the same use case with stronger evidence.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype) | SKIP | Liver protection not a stated priority; if it were, NAC (already in V4 stack) covers it. |
30-50, executive maintenance | SKIP | Use NAC + milk thistle + choline + reduce alcohol. Vastly more evidence, vastly cheaper. |
50+, mild cognitive decline | SKIP | for liver use case; if exploring full Khavinson stack as a curiosity, epithalon has marginally more data. |
Anxiety-prone | N | — |
High athletic load, tested status | SKIP | WADA status unclear for unscheduled gray-market peptide; better-evidenced options exist. |
Sleep-disordered | N | — |
Recovery-focused (post-injury, post-illness) | SKIP | NAC, glycine, glutathione precursors are better evidenced. |
Strength/anabolic-focused | N | — |
- Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)SKIP
Liver protection not a stated priority; if it were, NAC (already in V4 stack) covers it.
- 30-50, executive maintenanceSKIP
Use NAC + milk thistle + choline + reduce alcohol. Vastly more evidence, vastly cheaper.
- 50+, mild cognitive declineSKIP
for liver use case; if exploring full Khavinson stack as a curiosity, epithalon has marginally more data.
- Anxiety-proneN
- High athletic load, tested statusSKIP
WADA status unclear for unscheduled gray-market peptide; better-evidenced options exist.
- Sleep-disorderedN
- Recovery-focused (post-injury, post-illness)SKIP
NAC, glycine, glutathione precursors are better evidenced.
- Strength/anabolic-focusedN
▸ Subjective experience (deep)
Mostly silent — users do not report acute felt effects (consistent with most Khavinson peptides, which are pitched as long-arc gerontological tools rather than acute nootropics or felt-effect compounds). Some users report mild GI calm.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown / not characterized
- Recommended cycle: Khavinson group recommends 30-day courses 2-3×/year
- Reset protocol if needed: N/A
▸ Stacking deep dive
Synergistic with
- N/A — no credible interaction data.
Avoid stacking with
- N/A — no credible interaction data.
Neutral / safe co-administration
- Presumed safe with most things given short peptide nature, but this is a mechanistic guess, not a data-backed claim.
▸ Drug interactions deep dive
None characterized in Western literature. CYP interactions unknown.
▸ Pharmacogenomics
None characterized.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gray-market import | RUPharma | ~$30-50/30 caps | Medium | Khavinson-line peptides; standard gray-market shipping |
| Gray-market import | CosmicNootropic | ~$35-55/30 caps | Medium | Same product line, alternate vendor |
▸ Biomarkers to track (deep)
- Baseline (before starting): ALT, AST, GGT, bilirubin, albumin (standard liver panel).
- During use: Repeat liver panel mid-cycle and post-cycle if running anyway.
- Post-cycle (if cycled): Liver panel at 30 days post.
▸ Controversies / open debates Live debate
- Core controversy: The entire Khavinson short-peptide framework is contested. Western pharmacology has not validated the "tissue-specific oral peptide reaches nucleus" mechanism for any member of the family. Independent replication outside the Khavinson group is essentially zero.
- What would change the verdict: A Western-indexed RCT showing meaningful liver-marker improvements vs. placebo, OR a published amino-acid sequence with mechanistic data showing how the peptide reaches hepatocyte nuclei after oral administration.
- Steel-man: Russian gerontology literature has a different evidence culture; some Khavinson compounds (cortexin in particular) do have somewhat more clinical use behind them. Cerluten specifically is not in that better-evidenced subset.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-FOR-NOW LOW. Thin Russian-only evidence, contested framework, cleaner alternatives exist (NAC, milk thistle, choline) with vastly stronger evidence for the same use case.
▸ Open questions / gaps Open
- No published amino-acid sequence Western-indexed
- No bioavailability data
- No pharmacokinetic data
- No independent replication
- No comparative data vs. NAC / silymarin / phosphatidylcholine
▸ Sources (full, with our context)
PubMed-indexed Khavinson framework references (background, not Cerluten-specific)
- Khavinson VKh. "Peptides and Ageing." Neuro Endocrinol Lett 2002;23 Suppl 3:11-144. PMID: 12374906 — Foundational Khavinson framework paper covering the broad short-peptide bioregulator hypothesis under which Cerluten is positioned. Background reference; does not establish Cerluten-specific efficacy.
- Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology 2010;11(2):139-149. PMID: 19830585 — Khavinson group review of peptide bioregulator long-term geroprotective effects; broad framework support, no Cerluten-specific RCT data.
- Khavinson VKh, Kuznik BI, Tarnovskaya SI, Linkova NS. "[Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]." Adv Gerontol 2013;26(2):343-351. PMID: 24003726 — Khavinson framework clinical-results summary covering multiple peptide bioregulators; serves as the closest Western-indexed compendium reference for the family Cerluten belongs to. Critical caveat: single-source / no Western replication, all data from the Khavinson group.
- Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Int J Mol Sci 2022;23(7):3552. PMID: 35408914 — In vitro mechanism work on Khavinson short peptides; broad family-level support, no Cerluten-specific in vivo translation.
Note on Cerluten-specific evidence: No Cerluten-specific PubMed-indexed RCT exists as of 2026. The four PMIDs above establish the framework under which Cerluten is sold, not the drug. This is the core evidence gap that drives the SKIP-FOR-NOW LOW-confidence verdict.
Vendor + framework critique
- Khavinson V.Kh. publications (Russian-language, St. Petersburg Institute of Bioregulation and Gerontology) — primary advocacy literature
- RUPharma product page (vendor copy, not independent evidence)
- CosmicNootropic product page (vendor copy, not independent evidence)
- General critique of Khavinson framework: see notes on epithalon — same evidence-quality issues apply